H
ighly specialized pediatric centers are needed for the diagnosis and treatment of rare but life-threatening conditions, including malignant diseases, because children with these disorders require complex diagnostic procedures and high-end therapeutic interventions, such as stem cell transplantation.
1,2 Centralization of subspecialty care is instrumental to ensure the quality of care that correlates with experience and consequently with the number of rare cases diagnosed and treated, as is seen in pediatric oncology, as well as in maternal and neonatal care. 3, 4 Beyond such centralization, it was crucial to the success of pediatric oncology that centers started to cooperate and engage in prospective, randomized, and controlled multicenter clinical trials that included other subspecialties to work toward the best possible outcomes for children with cancer.
Because the resources available for pediatric subspecialty care are not equally available in all 53 European countries, the organization and the structure of care in pediatric oncology are heterogeneous. Therefore, in 2007 the European Paediatric Association/Union of National European Paediatric Societies and Associations (EPA/UNEPSA) investigated the pediatric oncology landscape of care in in 31 European countries. These data, presented at the 2011 EUROPAEDIATRICS congress in Vienna, 5 concluded that less well-resourced countries in Eastern Europe faced the dilemma of how best to develop and finance hematooncologic care in the future. Better-resourced countries in Western Europe faced the problem of how best to rationalize and colocate interdependent specialist services to improve outcomes. Last, but not least, small countries looked for ways of developing effective cross-border care.
Our goal is to inform the European pediatricians about previous findings and to reopen the debate on the structure of health care services for European children with malignant diseases. We hope to motivate national pediatric oncologists to support a new survey in 2017 on the development of health service systems in Europe during the last 10 years.
Human Workforce and Hospital Care
The almost 10-year-old EPA/UNEPSA survey covered 31 of the 53 countries (59%), with 632 million of the total 879 million European inhabitants (72%). The questionnaire was answered by members of International Society of Paediatric Oncology (52%), EPA/UNEPSA (39%), and other pediatric organizations (9%). The median number of fully trained and accredited pediatric hemato-oncologists (PHOs) was 18 PHO per million child population (pmcp), and there was no significant difference between Western European countries and Eastern European countries with a low gross domestic product (GDP); however, the proportion of PHO per total number of pediatricians was lower in Eastern Europe (1.3% vs 2.7%; P = .003). Eighty-four percent of PHOs worked in children's hospitals, compared with 43% of all pediatricians. The median number of specialized oncology centers was 3.3 pmcp (2.8 in the East and 3.8 in the West; P = .088). A median of 1.3 centers pmcp offered human stem cell transplantation, with a significant difference between Eastern and Western European countries (0.5 vs 1.7; P = .013). There was a positive correlation (r = 0.559; P < .001) between the number of stem cell transplantation pmcp and GDP.
Postgraduate Training, Registries, and Clinical Trials
Sixty percent of reporting countries fulfilled the European criteria for postgraduate subspecialty training in pediatric hematooncology. Continuous medical education was offered for these specialists in 80% of countries, and there was no significant difference in availability and accessibility of training between Eastern and Western Europe; however, the content of teaching and training sessions was not studied.
Ninety percent of the 31 countries had a national registry for malignancies in childhood, and one-third of these reported their statistics to international registries as well. In 25 European countries, the proportion of children with malignancies reported to a registry exceeded 90%, and less than 10% were not reported to any registry. The median incidence of malignancies during childhood was 15.2 per 100 000 children aged <15 years.
Prospective, randomized, and controlled multicenter clinical trials were in place in 27 of 31 countries, and approximately one-half of the children with malignancies were enrolled in these trials (range, 5%-100%). The number of trials and the proportion of children recruited into trials were lower in Eastern Europe compared with Western Europe. Seventyfour percent of countries reported follow-up care of pediatric oncology patients performed in specialized pediatric or adult oncology centers. Therapeutic guidelines for standardized diagnosis and treatment of children with malignancies were reported from 94% of countries.
Open Question on Financing and Provision of Services
Although the cost of care may be low for children in general, those with malignancies significantly influence the overall cost of care in pediatrics, 6 creating a considerable financial burden for national social health insurance systems. However, there is limited information concerning the variation of costs among European countries. The impact of GDP as well as the presence or absence of either a system of health insurance funds or a national health service may have an impact in this respect. Threequarters of the 31 European countries reported financing by health insurance funds and one-quarter by taxes and a national health service. There is also a lack of data on the influence of different health care systems on outcomes of care. Furthermore, the roles of major health system reforms and of health system assessment remain to be clarified. Pediatric oncologists of 65% of the countries reported that the quality of care in their own country was comparable to that of most other European countries, whereas the situation was estimated to be superior to average in 19% and lower than normal in 16% of countries. Unfortunately, the previous EPA/UNEPSA survey did not study the survival rates of children with different malignancies according to countries. When asking the reporting PHO what she or he considered the most important future challenges and wishes, the most frequent answer was "better working conditions" (Table) . Further research is needed to determine the optimal size of specialist centers for childhood malignancies based on the primary outcomes of effectiveness, equity, and efficiency, given varying circumstances, and the optimal population size covered by specialist centers. Research should also be undertaken to determine the colocation of hemato-oncological centers with other pediatric subspecialties. Integrating PHO centers into the traditional organizational structures of primary, secondary, and tertiary pediatric care is of utmost importance to avoid fragmentation of pediatric care. A future survey should analyze whether a successful network could include centralized management and decision making by specialized PHO teams with decentralized provision of treatment whenever possible.
There is a list of questions that had not been asked in the previous survey. Therefore, new questions should relate to the rights of children to health, such as consent to treatment, the role of rehabilitative and palliative care in special centers, social integration, and schooling, as well as differences in long-term care.
Conclusions
There is a need for a follow-up survey on the diversity of national child health care services for European children with malignancies that not only will repeat the previous questions, thus showing the developmental changes within the last 10 years, but also will add new questions that concentrate on differences in quality of care and outcomes, in training programs of caregivers, numbers and qualifications of all specialists, costs of treatment, quality measures relating to competence and service provision, future workforce planning, and the difficulties in achieving significant changes or reorganization in provision. EPA/ UNEPSA plans to start the new survey at the end of 2017. For further information, please visit the EPA/UNEPSA website in October 2017. ■ 
